Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck

M. Clavel, F. Cognetti, P. Dodion, J. Wildiers, R. Rosso, A. Rossi, B. Gignoux, M. Van Rymenant, H. Cortes-Funes, O. Dalesio, A. Kirkpatrick, M. Rozencweig

Research output: Contribution to journalArticle

Abstract

A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methotrexate (40 mg/m2; days 1, 15), bleomycin (10 mg; days 1, 8, and 15), and vincristine (2 mg; days 1, 8, and 15) and the ABO group received methotrexate, bleomycin and vincristine in the same doses on days 1, 8, and 15. After three courses, patients in both arms received weekly methotrexate as maintenance therapy; those 34 patients with previously untreated locoregional disease went off the study because of subsequent locoregional treatment in form of radiotherapy ± surgery. The complete response rate was 16% in patients receiving CABO, compared with 5% among patients given ABO. The corresponding overall response rates were 50% and 28%, respectively (P = 0.003). Among patients with recurrent or metastatic disease, progression was delayed in patients receiving CABO (median, 18 weeks) compared to those receiving ABO (median, 14 weeks) (P = 0.07), but there was no difference in survival time. Myelosuppression consisted mostly of leukopenia, which was seen in 67% of the CABO patients versus 47% in the other arm. Myelosuppression-associated infection and hemorrhage led to death in two patients in the CABO treatment group and six patients in the ABO treatment group. Nausea and vomiting, mostly of grades 1 or 2, occurred in 93% of the patients given CABO and 44% of those receiving ABO. Other toxic effects - neuropathy, alopecia, stomatitis, constipation, fever/chills, diarrhea, cutaneous alterations, and renal impairment - occurred equally in the two treatment groups. This study underlines the role of cisplatin in head and neck cancer, although no impact on survival could be demonstrated. It also supports indirectly the superiority of combination chemotherapy over single-agent treatment for this disease.

Original languageEnglish
Pages (from-to)1173-1177
Number of pages5
JournalCancer
Volume60
Issue number6
Publication statusPublished - 1987

Fingerprint

Bleomycin
Vincristine
Combination Drug Therapy
Methotrexate
Cisplatin
Carcinoma, squamous cell of head and neck
Therapeutics
Chills
Stomatitis
Survival
Poisons
Alopecia
Leukopenia
Constipation
Head and Neck Neoplasms
Nausea
Vomiting
Disease Progression
Diarrhea
Fever

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. / Clavel, M.; Cognetti, F.; Dodion, P.; Wildiers, J.; Rosso, R.; Rossi, A.; Gignoux, B.; Van Rymenant, M.; Cortes-Funes, H.; Dalesio, O.; Kirkpatrick, A.; Rozencweig, M.

In: Cancer, Vol. 60, No. 6, 1987, p. 1173-1177.

Research output: Contribution to journalArticle

Clavel, M, Cognetti, F, Dodion, P, Wildiers, J, Rosso, R, Rossi, A, Gignoux, B, Van Rymenant, M, Cortes-Funes, H, Dalesio, O, Kirkpatrick, A & Rozencweig, M 1987, 'Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck', Cancer, vol. 60, no. 6, pp. 1173-1177.
Clavel, M. ; Cognetti, F. ; Dodion, P. ; Wildiers, J. ; Rosso, R. ; Rossi, A. ; Gignoux, B. ; Van Rymenant, M. ; Cortes-Funes, H. ; Dalesio, O. ; Kirkpatrick, A. ; Rozencweig, M. / Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. In: Cancer. 1987 ; Vol. 60, No. 6. pp. 1173-1177.
@article{f36a6df540d04b3e8d616d5e633e10f2,
title = "Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck",
abstract = "A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methotrexate (40 mg/m2; days 1, 15), bleomycin (10 mg; days 1, 8, and 15), and vincristine (2 mg; days 1, 8, and 15) and the ABO group received methotrexate, bleomycin and vincristine in the same doses on days 1, 8, and 15. After three courses, patients in both arms received weekly methotrexate as maintenance therapy; those 34 patients with previously untreated locoregional disease went off the study because of subsequent locoregional treatment in form of radiotherapy ± surgery. The complete response rate was 16{\%} in patients receiving CABO, compared with 5{\%} among patients given ABO. The corresponding overall response rates were 50{\%} and 28{\%}, respectively (P = 0.003). Among patients with recurrent or metastatic disease, progression was delayed in patients receiving CABO (median, 18 weeks) compared to those receiving ABO (median, 14 weeks) (P = 0.07), but there was no difference in survival time. Myelosuppression consisted mostly of leukopenia, which was seen in 67{\%} of the CABO patients versus 47{\%} in the other arm. Myelosuppression-associated infection and hemorrhage led to death in two patients in the CABO treatment group and six patients in the ABO treatment group. Nausea and vomiting, mostly of grades 1 or 2, occurred in 93{\%} of the patients given CABO and 44{\%} of those receiving ABO. Other toxic effects - neuropathy, alopecia, stomatitis, constipation, fever/chills, diarrhea, cutaneous alterations, and renal impairment - occurred equally in the two treatment groups. This study underlines the role of cisplatin in head and neck cancer, although no impact on survival could be demonstrated. It also supports indirectly the superiority of combination chemotherapy over single-agent treatment for this disease.",
author = "M. Clavel and F. Cognetti and P. Dodion and J. Wildiers and R. Rosso and A. Rossi and B. Gignoux and {Van Rymenant}, M. and H. Cortes-Funes and O. Dalesio and A. Kirkpatrick and M. Rozencweig",
year = "1987",
language = "English",
volume = "60",
pages = "1173--1177",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck

AU - Clavel, M.

AU - Cognetti, F.

AU - Dodion, P.

AU - Wildiers, J.

AU - Rosso, R.

AU - Rossi, A.

AU - Gignoux, B.

AU - Van Rymenant, M.

AU - Cortes-Funes, H.

AU - Dalesio, O.

AU - Kirkpatrick, A.

AU - Rozencweig, M.

PY - 1987

Y1 - 1987

N2 - A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methotrexate (40 mg/m2; days 1, 15), bleomycin (10 mg; days 1, 8, and 15), and vincristine (2 mg; days 1, 8, and 15) and the ABO group received methotrexate, bleomycin and vincristine in the same doses on days 1, 8, and 15. After three courses, patients in both arms received weekly methotrexate as maintenance therapy; those 34 patients with previously untreated locoregional disease went off the study because of subsequent locoregional treatment in form of radiotherapy ± surgery. The complete response rate was 16% in patients receiving CABO, compared with 5% among patients given ABO. The corresponding overall response rates were 50% and 28%, respectively (P = 0.003). Among patients with recurrent or metastatic disease, progression was delayed in patients receiving CABO (median, 18 weeks) compared to those receiving ABO (median, 14 weeks) (P = 0.07), but there was no difference in survival time. Myelosuppression consisted mostly of leukopenia, which was seen in 67% of the CABO patients versus 47% in the other arm. Myelosuppression-associated infection and hemorrhage led to death in two patients in the CABO treatment group and six patients in the ABO treatment group. Nausea and vomiting, mostly of grades 1 or 2, occurred in 93% of the patients given CABO and 44% of those receiving ABO. Other toxic effects - neuropathy, alopecia, stomatitis, constipation, fever/chills, diarrhea, cutaneous alterations, and renal impairment - occurred equally in the two treatment groups. This study underlines the role of cisplatin in head and neck cancer, although no impact on survival could be demonstrated. It also supports indirectly the superiority of combination chemotherapy over single-agent treatment for this disease.

AB - A total of 185 eligible patients with advanced inoperable squamous cell carcinoma of the head and neck were randomized into two groups; the cisplatin, methotrexate, bleomycin, and vincristine (CABO) group received cisplatin (50 mg/m2; day 4), methotrexate (40 mg/m2; days 1, 15), bleomycin (10 mg; days 1, 8, and 15), and vincristine (2 mg; days 1, 8, and 15) and the ABO group received methotrexate, bleomycin and vincristine in the same doses on days 1, 8, and 15. After three courses, patients in both arms received weekly methotrexate as maintenance therapy; those 34 patients with previously untreated locoregional disease went off the study because of subsequent locoregional treatment in form of radiotherapy ± surgery. The complete response rate was 16% in patients receiving CABO, compared with 5% among patients given ABO. The corresponding overall response rates were 50% and 28%, respectively (P = 0.003). Among patients with recurrent or metastatic disease, progression was delayed in patients receiving CABO (median, 18 weeks) compared to those receiving ABO (median, 14 weeks) (P = 0.07), but there was no difference in survival time. Myelosuppression consisted mostly of leukopenia, which was seen in 67% of the CABO patients versus 47% in the other arm. Myelosuppression-associated infection and hemorrhage led to death in two patients in the CABO treatment group and six patients in the ABO treatment group. Nausea and vomiting, mostly of grades 1 or 2, occurred in 93% of the patients given CABO and 44% of those receiving ABO. Other toxic effects - neuropathy, alopecia, stomatitis, constipation, fever/chills, diarrhea, cutaneous alterations, and renal impairment - occurred equally in the two treatment groups. This study underlines the role of cisplatin in head and neck cancer, although no impact on survival could be demonstrated. It also supports indirectly the superiority of combination chemotherapy over single-agent treatment for this disease.

UR - http://www.scopus.com/inward/record.url?scp=0023616584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023616584&partnerID=8YFLogxK

M3 - Article

C2 - 2441836

AN - SCOPUS:0023616584

VL - 60

SP - 1173

EP - 1177

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -